Some studies of smaller gene sets found abnormal expression of TP53 in LCLC and LCNEC tumors, with KRAS mutations predominating in LCLC (Iyoda et al., 2004; Rossi et al., 2014). This evidence concerns the gene TP53 and large cell neuroendocrine carcinoma.